Lindner, S. M., & Hacke, W. (2017). Treatment consistency across levels of baseline renal function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis. Circulation, 135(10), . https://doi.org/10.1161/CIRCULATIONAHA.116.024666
Chicago-Zitierstil (17. Ausg.)Lindner, Samuel M., und Werner Hacke. "Treatment Consistency Across Levels of Baseline Renal Function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis." Circulation 135, no. 10 (2017). https://doi.org/10.1161/CIRCULATIONAHA.116.024666.
MLA-Zitierstil (9. Ausg.)Lindner, Samuel M., und Werner Hacke. "Treatment Consistency Across Levels of Baseline Renal Function with Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis." Circulation, vol. 135, no. 10, 2017, https://doi.org/10.1161/CIRCULATIONAHA.116.024666.